過(guò)氧化還原酶2(PRDX2)單克隆抗體
Monoclonal Antibody to Peroxiredoxin 2 (PRDX2)
PRP; NKEFB; PRXII; TDPX1; TSA; Thioredoxin-Dependent Peroxide Reductase 1; Thiol-Specific Antioxidant 1; Natural Killer-Enhancing Factor B; Thioredoxin Peroxidase 1; Torin
- 編號(hào)MAF757Hu23
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))C3
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPF757Hu03-過(guò)氧化還原酶2(PRDX2)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 644 ¥ 1504 ¥ 2148 ¥ 5370 ¥ 21480
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Western Blot; Samples: Lane1: C2C12 cell lysate; Lane2: MCF7 cell lysate; Lane3: Hela cell lysate; Lane4: HepG2 cell lysate;
Primary Ab: 0.2μg/ml Mouse Anti-Human PRDX2 Antibody
Second Ab: 0.2μg/ml HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)PRDX2的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別PRDX2。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPF757Hu02 | 過(guò)氧化還原酶2(PRDX2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPF757Hu03 | 過(guò)氧化還原酶2(PRDX2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPF757Hu01 | 過(guò)氧化還原酶2(PRDX2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAF757Hu01 | 過(guò)氧化還原酶2(PRDX2)多克隆抗體 | WB; IHC; ICC; IP. |
| PAF757Hu03 | 過(guò)氧化還原酶2(PRDX2)多克隆抗體 | WB; IHC; ICC; IP. |
| PAF757Hu02 | 過(guò)氧化還原酶2(PRDX2)多克隆抗體 | WB; IHC; ICC; IP. |
| FAF757Hu03 | 抗過(guò)氧化還原酶2(PRDX2)多克隆抗體 | Flow cytometry. |
| MAF757Hu23 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu22 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu21 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB |
| MAF757Hu24 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu25 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu26 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu27 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu28 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAF757Hu29 | 過(guò)氧化還原酶2(PRDX2)單克隆抗體 | WB; IHC; ICC; IP. |
| WEF757Hu | 過(guò)氧化還原酶2(PRDX2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SEF757Hu | 過(guò)氧化還原酶2(PRDX2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMF757Hu | 過(guò)氧化還原酶2(PRDX2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Free Radical Research | Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress [Pubmed:25564095] |
| PLoS One | Differences in Proinflammatory Property of Six Subtypes of Peroxiredoxins and Anti-Inflammatory Effect of Ligustilide in Macrophages [pubmed:27716839] |
| Experiental And Therapeutic Medicine | Plasma proteins as potential targets of abnormal Savda syndrome in asthma patients treated with unique Uighur prescription [pubmed:28672924] |
| Oncotarget | Neuroprotective effect of a novel gastrodin derivative against ischemic brain injury: involvement of peroxiredoxin and TLR4 signaling inhibition [pubmed:29207618] |
| European Journal of Applied Physiology | Prolonged forearm ischemia attenuates endothelium-dependent vasodilatation and plasma nitric oxide metabolites in overweight middle-aged men [Pubmed:29785503] |
| Journal of Applied Physiology | Montmorency cherry supplementation attenuates vascular dysfunction induced by prolonged forearm occlusion in overweight middle-aged men [Pubmed: 30496705] |
| ACS Omega | SOD1 is a Possible Predictor of COVID-19 Progression as Revealed by Plasma Proteomics [34250342] |
